Squamous Cell Carcinoma of the Oropharynx Clinical Trial
— MOSESOfficial title:
Evaluation of the Role of Tongue Base MucOsectomy and Step sErial Sectioning in the Management of the Unknown Primary Squamous Cell Cancer in the Head and Neck
NCT number | NCT04151134 |
Other study ID # | CCR5065 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 1, 2019 |
Est. completion date | December 1, 2028 |
Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck. Clinical examination and imaging investigations are performed to try and identify the site where the cancer has originated. However, if no original site can be identified, then the investigators call these 'cancers of an unknown primary' (CUP) of the head and neck. One region where these cancers could have originated from is the oropharynx. There are two areas in the oropharynx were cancers commonly arise. One area is the palatine tonsils, which can be removed for analysis with an operation called tonsillectomy. The other area is the tissue lining the back of the tongue, known as the tongue base. A relatively new surgical technique called 'tongue base mucosectomy' (TBM) allows removal of this tissue to see if the primary cancer is contained within it. This study will then use a histological method called 'step serial sectioning' (SSS) to look in more detail at the tonsils and tongue base, hoping to increase the detection rate of the primary cancer. Centres performing TBM will be asked to participate. Patients will be asked to consent to their tissue being used for SSS after it has undergone conventional histology. Anonymised samples will be sent to a central laboratory in Newcastle for processing. Other anonymised data regarding the patients' diagnosis and care will be collated. Patients will be asked to complete questionnaires regarding pain and swallowing recovery following surgery. A smaller cohort of patients will also be interviewed as part of a qualitative research process to establish their views on CUP and the acceptability of the above treatment.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 1, 2028 |
Est. primary completion date | December 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Aged 16 or over - Both sexes - Cervical metastatic SCC, confirmed with cytology or biopsy, undergoing TBM for identification of primary site Exclusion Criteria: - Primary site identified by any means prior to being indicated for TBM - Patients undergoing targeted biopsies or resections - Patients known to have a history of previous H&N cancers - Patients known to have undergone previous radiation to the H&N region |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals Birmingham NHS Foundation Trust | Birmingham |
Lead Sponsor | Collaborator |
---|---|
Royal Marsden NHS Foundation Trust | Institute of Cancer Research, United Kingdom, Oracle Cancer Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Primary Cancers Identified | Cancer identified in tonsil and tongue base resections | Within one year of surgery | |
Secondary | Pain after tongue base mucosectomy | Numeric Pain Scale. A person rates their pain on a scale of 0 to 10 | week 0 , 3 weeks, 6 weeks, 12 weeks, 26 weeks and 52 weeks | |
Secondary | Swallow function after tongue base mucosectomy | Patients will be given the MDADI questionnaire in which they will be asked a series of questions with the following possible answers: completely agree, agree, uncertain, disagree, completely disagree | week 0 , 3 weeks, 6 weeks, 12 weeks, 26 weeks and 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03669718 -
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
|
Phase 2 | |
Withdrawn |
NCT01586182 -
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
Recruiting |
NCT05119036 -
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04031534 -
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
Terminated |
NCT02552550 -
Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
|
||
Active, not recruiting |
NCT04398524 -
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
|
Phase 2 | |
Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
Completed |
NCT01663259 -
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
|
N/A | |
Recruiting |
NCT04104945 -
p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)
|
N/A | |
Not yet recruiting |
NCT05962242 -
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06061705 -
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
|
N/A | |
Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112535 -
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
|
N/A | |
Completed |
NCT01921426 -
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
|
Phase 1 | |
Completed |
NCT01181648 -
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
|
||
Recruiting |
NCT05918510 -
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
|
||
Recruiting |
NCT05894083 -
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
|
Phase 2 |